Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells (Q59801804)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 November 2018

Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells

Language	Label	Description	Also known as
English	Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells	scientific article published on 29 November 2018	Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

author name string

Ling Li

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Jingkui Yu

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Shuhong Jiao

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Wei Wang

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Fen Zhang

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Shiqing Sun

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

language of work or name

0 references

publication date

29 November 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

OncoTargets and Therapy

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

8543-8553

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 November 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

describes a project that uses

1 reference

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6278704/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib therapy in medullary thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The discovery and development of vandetanib for the treatment of thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF-induced intracellular Ca2+ oscillations are down-regulated and do not stimulate angiogenesis in breast cancer-derived endothelial colony forming cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In Situ shRNA Synthesis on DNA-Polylactide Nanoparticles to Treat Multidrug Resistant Breast Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Opposite response to hypoxia by breast cancer cells between cell proliferation and cell migration: A clue from microRNA expression profile.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential role of Polo-like kinase 1 (Plk1) oncogene in tumor growth and metastasis of tamoxifen-resistant breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis - a crucial step in breast cancer growth, progression and dissemination by Raman imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30555244

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/OTT.S175578

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30555244%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59801804&oldid=1890122927"